The right drugs at the right time for the right patient: The MD Anderson precision oncology decision support platform

Amber Johnson, Jia Zeng, Ann M. Bailey, Vijaykumar Holla, Beate Litzenburger, Humberto Lara-Guerra, Gordon B. Mills, John Mendelsohn, Kenna R. Shaw, Funda Meric-Bernstam

    Research output: Contribution to journalShort survey

    33 Scopus citations

    Abstract

    The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.

    Original languageEnglish (US)
    Pages (from-to)1433-1438
    Number of pages6
    JournalDrug Discovery Today
    Volume20
    Issue number12
    DOIs
    StatePublished - Dec 1 2015

      Fingerprint

    ASJC Scopus subject areas

    • Pharmacology
    • Drug Discovery

    Cite this

    Johnson, A., Zeng, J., Bailey, A. M., Holla, V., Litzenburger, B., Lara-Guerra, H., Mills, G. B., Mendelsohn, J., Shaw, K. R., & Meric-Bernstam, F. (2015). The right drugs at the right time for the right patient: The MD Anderson precision oncology decision support platform. Drug Discovery Today, 20(12), 1433-1438. https://doi.org/10.1016/j.drudis.2015.05.013